# Pulse Biosciences, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Pulse Biosciences, Inc). ## Overview Pulse Biosciences is a U.S.-based medical technology company focused on developing and commercializing nonthermal pulsed field ablation systems. Its platform includes the nPulse system and related disposable electrodes for use in surgical and minimally invasive procedures, with applications in cardiac arrhythmia treatment and soft-tissue ablation. ## Products & services • nPulse System for nonthermal pulsed field ablation • nPulse Vybrance Percutaneous Electrode System • Disposable electrode consumables • Clinical and product development for AF and soft-tissue ablation - **Pulsed field ablation systems** (45%) — Console-based systems used to deliver nonthermal energy for tissue ablation. - **Disposable electrode products** (35%) — Single-use electrodes and related consumables used with the company's platform. - **Clinical-stage product development** (20%) — Development programs for atrial fibrillation, tumors, and nodules. - nPulse System for nonthermal pulsed field ablation - nPulse Vybrance Percutaneous Electrode System - Disposable electrode consumables - Clinical and product development for AF and soft-tissue ablation ## Customers The company sells into clinical end markets that use ablation technologies, especially electrophysiology, cardiac surgery, and minimally invasive surgery. Its buyers are hospitals, physicians, and procedural specialists that need devices for treating atrial fibrillation and other soft-tissue conditions. The business also depends on clinical investigators and trial sites that support product development and regulatory progress. - **Electrophysiology practices** (primary) — Buy ablation systems for atrial fibrillation procedures and value differentiated energy delivery. - **Hospitals and surgical centers** (primary) — Use the platform in procedural settings for cardiac and soft-tissue ablation. - **Cardiac surgeons** (secondary) — Adopt the system for surgical ablation workflows where direct support and training matter. - **Clinical research sites** (secondary) — Support trials and early clinical use of the company's product candidates. - Hospitals and surgical centers performing ablation procedures - Electrophysiologists treating atrial fibrillation - Cardiac surgeons and interventional specialists - Clinical trial sites and investigators supporting development - Physicians seeking nonthermal tissue ablation tools ## Geography Pulse Biosciences is headquartered in the United States, with corporate offices in Miami, Florida. The reports indicate a domestic and international commercialization ambition, but no country-level revenue disclosure was provided in the excerpts. Geography matters because the company must build sales, clinical, regulatory, and support capabilities across markets where ablation adoption and reimbursement can differ. - Headquartered in Miami, Florida, United States - U.S. market is central for clinical adoption and commercialization - International expansion is part of the sales and support model - Clinical and regulatory requirements vary by country - No country-level revenue split was disclosed in the excerpts ## Strategy The company is focused on advancing its nonthermal pulsed field ablation platform into marketable products for atrial fibrillation, tumors, and nodules. A key priority is building clinical evidence and product performance that can compete against established ablation technologies while expanding sales, marketing, and support capabilities. It also relies on third-party relationships and direct sales execution to translate development progress into adoption. - **Develop marketable products for AF and soft-tissue ablation** (medium-term) — Commercial success depends on turning the platform into approved, usable products. - **Differentiate against micro-PFA and thermal ablation competitors** (short-term) — The market is crowded and technology cycles are fast, so performance advantages matter. - **Expand sales, marketing, and clinical support** (short-term) — Adoption in procedural medicine depends on training, relationships, and hands-on support. - Advance nPulse-based products through clinical and product development - Target atrial fibrillation and soft-tissue ablation applications - Differentiate with nonthermal, deeper, and more efficient ablation - Build direct sales and technical support capabilities - Use third parties where needed for manufacturing and distribution ## Risks The company faces substantial product-development and commercialization risk because its platform must prove safety, efficacy, and clinical utility against larger competitors with more resources. It also faces execution risk in sales, manufacturing, and distribution, along with litigation, product liability, and insurance coverage constraints that are common in medical devices. Accounting risk is elevated by goodwill and intangible asset impairment exposure, stock-based estimates, and judgment-heavy disclosures tied to a development-stage business. - **Product development failure** [critical] — The business depends on creating marketable products for AF and other indications. - **Competitive displacement** [high] — Established ablation companies have greater resources and faster product cycles. - **Product liability and clinical trial claims** [high] — Medical devices can cause adverse events and trigger litigation or insurance losses. - **Commercialization and channel execution** [medium] — Sales depend on trained reps, distributors, and direct procedural support. - Clinical and regulatory setbacks could delay or block commercialization - Large competitors may outspend or out-innovate the platform - Product liability claims could exceed insurance coverage - Sales force and distributor execution risk can slow adoption - Goodwill and intangibles may be impaired if expectations weaken ## Accounting The most important accounting issues are impairment testing for goodwill and intangible assets, which can materially change reported asset values if product or market expectations weaken. The company also relies on judgment in estimating contingencies, litigation exposure, and insurance recoverability, while stock ownership changes can affect the usability of net operating losses under Section 382. As a development-stage medical device company, it may also face significant quarter-to-quarter variability in expenses tied to clinical work, product development, and commercialization efforts. - **Goodwill and intangible asset impairment** — Could create non-cash charges and reduce reported asset values - **Contingencies and product liability reserves** — Affects liabilities, expenses, and perceived financial strength - **Section 382 net operating loss limitations** — May limit future tax benefit recognition - Goodwill impairment testing can reduce reported assets and equity - Intangible asset valuation depends on product and market assumptions - Contingent liabilities and litigation estimates affect reserves - Insurance recoverability is uncertain for product and trial claims - Section 382 limits may affect use of net operating losses --- *Last updated: 2026-04-29T04:47:18.650632+00:00*